These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38956543)

  • 21. An EQ-5D-5L Value Set for Ghana Using an Adapted EuroQol Valuation Technology Protocol.
    Addo R; Mulhern B; Norman R; Owusu R; Viney R; Nonvignon J
    Value Health Reg Issues; 2024 Sep; 45():101045. PubMed ID: 39236574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
    Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
    Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UK Valuation of EQ-5D-5L, a Generic Measure of Health-Related Quality of Life: A Study Protocol.
    Rowen D; Mukuria C; Bray N; Carlton J; Cooper S; Longworth L; Meads D; O'Neill C; Yang Y
    Value Health; 2023 Nov; 26(11):1625-1635. PubMed ID: 37722593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
    Karim S; Craig BM; Groothuis-Oudshoorn CGM
    Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy SA; Abbassi MM; Finch AP; Baines D; Farid SF
    Pharmacoeconomics; 2021 May; 39(5):549-561. PubMed ID: 33709283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating a social value set for EQ-5D-5L in Sweden.
    Sun S; Chuang LH; Sahlén KG; Lindholm L; Norström F
    Health Qual Life Outcomes; 2022 Dec; 20(1):167. PubMed ID: 36564844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
    Craig BM; Rand K
    Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An EQ-5D-5L Value Set for Vietnam.
    Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
    Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
    Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
    J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The EQ-5D-5L valuation study in Korea.
    Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
    Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valuing health-related quality of life: An EQ-5D-5L value set for England.
    Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
    Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.